Several possible studies
Story checked
Diabetic GLP-1 use linked to increased hair loss risk | Penn Medicine (opens in a new tab)
pennmedicine.org · 2026-08-31
Short answer
Several possible studiesNo confirmed study match.
Several papers could fit this story, but none could be confirmed as its source. The claims remain unverified.
These papers were considered as possible sources, but none could be confirmed as the study behind this story.
Share this check
The story
Diabetic GLP-1 use linked to increased hair loss risk | Penn Medicine
pennmedicine.org · 2026-08-31
The story’s checkable claims.
Read the original story (opens in a new tab)NewsLink checks it
Several studies could be the source of this story.
More than one paper fits the article's details, and none fits well enough to single out. Checking claims against the wrong study would be worse than not checking them at all.
Open claim evidenceSearch result
Several studies could fit.
More than one paper fits the article's details, and none fits well enough to single out. Checking claims against the wrong study would be worse than not checking them at all.
Source layer
The paper behind the story
The source record for this check.
The research anchor for the report.
- Points somewhere elsepresented as the new finding
https://www.bmj.com/content/394/bmj-2026-100077
Evidence layer
Claim by claim
What the story asserts. With no source study, there is nothing to check these against.
Reading mode
Scan verdicts. Open evidence only when needed.
Claim 1 of 6Not checkedDoctors had heard anecdotal evidence that some patients taking GLP-1 medications were experiencing hair loss, and new research now shows the risk is real, albeit muted.View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 2 of 6Not checkedPatients with type 2 diabetes treated with GLP-1 medications were more likely to lose their hair than when they were treated with other diabetes medications.View evidenceHide evidence
As statedmore likely
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 3 of 6Not checkedIn one comparison, GLP-1 users were almost 70 percent more likely to have hair loss.View evidenceHide evidence
As statedalmost 70 percent more likely
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 4 of 6Not checkedCompared with SGLT2 inhibitors, GLP-1 users were 37 percent more likely to report hair loss, and compared with DPP4 inhibitors they were 68 percent more likely to have hair loss.View evidenceHide evidence
As stated37 percent; 68 percent
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 5 of 6Not checkedThe findings were consistent across age and sex.View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 6 of 6Not checkedThe researchers suggested weight loss may explain the hair loss, but also said the drug could cause hair loss through a different mechanism that needs to be explored.View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Method layer
No single source study was found.
The search results are available for you to inspect. Without a confirmed source study, they cannot establish whether the story’s claims are supported or contradicted.
Search results
Candidate papers, not confirmed sources.
PubMed, Crossref, Europe PMC · 15 candidate papers
Cutaneous Effects and Aesthetic Management of Glucagon-like Peptide-1 Receptor Agonists: A Narrative Review.
Clinics in Dermatology · 2026 · PubMed
Combination of Premixed Insulin with Glucagon-Like Peptide-1 Receptor Agonist (GLP-1) for Uncontrolled Type 2 Diabetes Mellitus (T2DM) Patients
Diabetes · 2018 · Crossref
Hair Loss in Patients on Glucagon-Like Peptide 1 Receptor Agonists: Understanding Risks and Managing Outcomes.
Dermatology and Therapy · 2026 · PubMed, Europe PMC
Integrating glucagon-like peptide-1 receptor agonists into dermatology practice: Safety and monitoring strategies.
Clinics in Dermatology · 2026 · PubMed
3-PUB: Plasma MMP-9 Concentration Is Reduced by GLP-1 Receptor Agonist Treatment in People with Type 2 Diabetes Mellitus
Diabetes · 2026 · Crossref